Burkitt lymphoma

Lore & Background

Burkitt lymphoma is classified into three main clinical variants: endemic, sporadic, and immunodeficiency-associated. The endemic variant, also called the African variant, most commonly occurs in children living in regions where malaria is endemic, such as equatorial Africa, Brazil, and Papua New Guinea. Epstein-Barr virus infection is found in nearly all patients with this variant, and chronic malaria is believed to reduce resistance to EBV. The disease characteristically involves the jaw or other facial bones, abdomen, and other organs, with less than 10% of cases presenting with central nervous system involvement.

Reader's Guide

The sporadic type is the most common variant in regions where malaria is not endemic, such as North America and parts of Europe. It has a median onset at age 10, with additional peaks at ages 40 and 75, and affects males 3–4 times more often than females. The abdominal region, particularly the right lower quadrant, is the most common site of involvement. The immunodeficiency-associated variant is usually linked to HIV infection but can also occur in post-transplant patients, with a median onset between 40–45 years and equal prevalence in males and females.

Did You Know?

• Almost all cases of Burkitt lymphoma involve dysregulation of the c-myc gene via one of three chromosomal translocations.
• The endemic variant is almost always associated with Epstein-Barr virus infection.
• Bcl-2 translocations, common in follicular lymphomas, do not occur in Burkitt lymphoma.
• Mutations in TCF3 and its negative regulator ID3 are found in about 70% of cases and are rarely seen in other aggressive B-cell lymphomas.

The Surgeon Who Gave It a Name

Burkitt lymphoma takes its name from Denis Parsons Burkitt, an Irish surgeon who first characterized the disease in 1958 while practicing in equatorial Africa. His observations laid the groundwork for what would become one of the most recognizable aggressive cancers of the lymphatic system. The malignancy targets B lymphocytes residing in the germinal center, and its rapid, destructive course distinguishes it from slower-growing lymphomas. Although Burkitt first encountered it in children across the African continent, the disease is not confined to that region or age group. In developed nations, where modern chemotherapy protocols are available, the overall cure rate hovers around ninety percent, a remarkable figure for a cancer once considered nearly universally fatal. The prognosis, however, shifts unfavorably when the disease strikes adults, who tend to experience a more difficult course than their younger counterparts. Burkitt's original fieldwork in the tropics remains a foundational chapter in hematology, illustrating how a single clinician's careful documentation can reshape an entire field's understanding of a disease.

Three Faces of One Disease

Clinicians divide Burkitt lymphoma into three clinical variants—the endemic, sporadic, and immunodeficiency-associated forms—yet under the microscope all three look remarkably similar in morphology, immunophenotype, and genetic profile. The endemic form, sometimes called the African variant, predominantly affects children in malaria-endemic regions such as equatorial Africa, Brazil, and Papua New Guinea, and characteristically involves the jaw, facial bones, or abdominal organs including the cecum, distal ileum, ovaries, kidney, and breast. The sporadic variant dominates in North America and parts of Europe, with a median onset around age ten but secondary peaks at forty and seventy-five; males are three to four times more likely to be affected than females, and the abdominal region—often the right lower quadrant—is the most common site. The immunodeficiency-associated variant typically arises in the context of HIV or post-transplant immunosuppression, strikes between ages forty and forty-five, affects both sexes equally, and accounts for roughly forty percent of all HIV-related lymphomas.

The Virus in the Driver's Seat

Epstein-Barr virus occupies a central, if complex, role in Burkitt lymphoma. In the endemic variant, EBV is detected in nearly every case, and the prevailing explanation is that chronic malaria weakens the host's immune surveillance, permitting the virus to infect B cells unchecked. The sporadic variant carries a far lower EBV association—roughly twenty to thirty percent of cases, most often in adults over fifty—while the immunodeficiency-associated form shows the virus in about twenty-five to forty percent of patients. Because a meaningful fraction of Burkitt lymphomas arise without any detectable EBV, researchers caution that the virus may sometimes be an innocent passenger rather than a causal agent. Yet the near-universal presence of EBV in the endemic form, combined with recent findings that the mutational landscape of EBV-positive and EBV-negative tumors differs significantly, strongly supports the idea that the virus actively contributes to the origin or progression of at least some cases. Burkitt lymphoma is therefore classified as one form among the broader family of EBV-associated lymphoproliferative diseases.

The MYC Translocation and the Road to Proliferation

Nearly every case of Burkitt lymphoma harbors a chromosomal translocation that places the c-myc oncogene, normally located at 8q24, under the control of an immunoglobulin gene enhancer. The most frequent rearrangement, t(8;14), accounts for seventy to eighty percent of cases and moves myc to the Ig heavy-chain locus on chromosome fourteen; t(2;8) involving the Ig kappa locus appears in about fifteen percent; and the rarer t(8;22) linking myc to the Ig lambda locus on chromosome twenty-two is found in roughly five percent. By relocating c-myc next to powerful enhancers, these translocations drive overexpression of a transcription factor that upregulates aerobic glycolysis, fueling the relentless cellular proliferation characteristic of the disease. Point mutations in the translocated gene can further amplify its activity. Importantly, Bcl-2 translocations—hallmarks of follicular lymphoma—are absent here. However, the MYC rearrangement alone is insufficient to cause malignancy; additional hits, particularly mutations in the TP53 tumor-suppressor pathway, are required to block the apoptotic death that would otherwise eliminate the aberrant B cells.